SCHEMBL2864115

SCHEMBL2864115

NCCNC(=O)c1ccc(Nc2ncc(CNc3cc(C(=O)NC4CC4)c(F)cc3F)s2)nc1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.71
PDGFRB P09619 1/20 0.71
KIT P10721 1/20 0.71
FLT1 P17948 1/20 0.71
KCNH2 Q12809 1/20 0.71
GABRA5 P31644 4/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TYK2 P29597 1/20 0.39
CHEK1 O14757 3/20 0.37
CDK7 P50613 2/20 0.37
MAPK14 Q16539 2/20 0.37
BUB1 O43683 1/20 0.37
CYP2C9 P11712 1/20 0.37
PRKACG P22612 1/20 0.37
MAPKAPK2 P49137 1/20 0.37
MAPK11 Q15759 1/20 0.37
ACSL5 Q9ULC5 1/20 0.37
STK24 Q9Y6E0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2881203 0.92 KDR (0.69) KDRPDGFRBKITFLT1KCNH2
SCHEMBL2862369 0.91 KDR (0.68) KDRPDGFRBKITFLT1KCNH2
SCHEMBL2864135 0.91 KDR (0.68) KDRPDGFRBKITFLT1KCNH2
SCHEMBL2853768 0.90 KDR (0.73) KDRPDGFRBKITFLT1KCNH2
SCHEMBL2855759 0.90 KDR (0.76) KDRPDGFRBKITFLT1KCNH2
SCHEMBL2859425 0.89 KDR (0.71) KDRPDGFRBKITFLT1KCNH2
SCHEMBL3913172 0.88 KDR (0.68) KDRPDGFRBKITFLT1KCNH2
SCHEMBL13513609 0.87 KDR (0.73) KDRPDGFRBKITFLT1KCNH2
SCHEMBL2862543 0.86 KDR (0.77) KDRPDGFRBKITFLT1KCNH2
SCHEMBL2863021 0.85 KDR (0.70) KDRPDGFRBKITFLT1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513818-B1 HETEROCYCLIC INHIBITORS OF VEGFR-2 KINASES BRISTOL MYERS SQUIBB CO (US) 2010-01-20 EP disclosed
US-7547711-B2 Heterocyclic inhibitors of kinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-16 US disclosed
US-7084160-B2 Heterocyclic inhibitors of kinases BRISTOL-MYERS SQUIBB COMPANY (US) 2006-08-01 US disclosed
US-20060135576-A1 Heterocyclic inhibitors of kinases BORZILLERI ROBERT M 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135576-A1 Heterocyclic inhibitors of kinases FGFR1, FLT1, FGFR2 KDR 7/4885PDGFRB 27/4885KIT 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.